MX391851B - Gliceril 3-hidroxibutiratos para las lesiones cerebrales traumaticas - Google Patents

Gliceril 3-hidroxibutiratos para las lesiones cerebrales traumaticas

Info

Publication number
MX391851B
MX391851B MX2019008269A MX2019008269A MX391851B MX 391851 B MX391851 B MX 391851B MX 2019008269 A MX2019008269 A MX 2019008269A MX 2019008269 A MX2019008269 A MX 2019008269A MX 391851 B MX391851 B MX 391851B
Authority
MX
Mexico
Prior art keywords
brain injury
traumatic brain
hydroxybutyrates
glyceryl
mild
Prior art date
Application number
MX2019008269A
Other languages
English (en)
Spanish (es)
Other versions
MX2019008269A (es
Inventor
Sami Hashim
Original Assignee
Neuroenergy Ventures Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuroenergy Ventures Inc filed Critical Neuroenergy Ventures Inc
Publication of MX2019008269A publication Critical patent/MX2019008269A/es
Publication of MX391851B publication Critical patent/MX391851B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225Polycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2019008269A 2017-01-12 2017-11-30 Gliceril 3-hidroxibutiratos para las lesiones cerebrales traumaticas MX391851B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/404,396 US9925164B1 (en) 2017-01-12 2017-01-12 Glyceryl 3-hydroxybutyrates for traumatic brain injury
PCT/US2017/063853 WO2018132189A1 (en) 2017-01-12 2017-11-30 Glyceryl 3-hydroxybutyrates for traumatic brain injury

Publications (2)

Publication Number Publication Date
MX2019008269A MX2019008269A (es) 2019-09-13
MX391851B true MX391851B (es) 2025-03-21

Family

ID=61633011

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008269A MX391851B (es) 2017-01-12 2017-11-30 Gliceril 3-hidroxibutiratos para las lesiones cerebrales traumaticas

Country Status (11)

Country Link
US (3) US9925164B1 (https=)
EP (1) EP3568129A4 (https=)
JP (1) JP7278593B2 (https=)
KR (1) KR102443942B1 (https=)
CN (1) CN110114067A (https=)
BR (1) BR112019014128A2 (https=)
CA (1) CA3046355C (https=)
IL (1) IL267934B2 (https=)
MX (1) MX391851B (https=)
MY (1) MY207193A (https=)
WO (1) WO2018132189A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
CA3021784A1 (en) * 2016-04-19 2017-10-26 Keto Patent Group, Inc. Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US12599579B2 (en) 2016-04-19 2026-04-14 Axcess Global Sciences, Llc Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
US10376528B2 (en) 2017-03-10 2019-08-13 Tecton Group, Llc Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor
US12171735B2 (en) 2017-04-19 2024-12-24 Axcess Global Sciences, Llc Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans
GB201715654D0 (en) 2017-09-27 2017-11-08 Tdeltas Ltd Method of treatment
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
BR112021014012A2 (pt) * 2019-01-17 2021-09-21 Ioi Oleo Gmbh Processo para a produção de lipídeos que contêm unidades estruturais com base em glicerídeos de ácidos hidroxicarboxílicos
ES2941943T3 (es) * 2019-01-17 2023-05-26 Ketolipix Therapeutics Gmbh Método para la producción de glicéridos de ácidos hidroxicarboxílicos
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
PL3976021T3 (pl) * 2019-05-30 2025-07-21 Neuroenergy Ventures, Inc. Tri(beta-hydroksymaślan) glicerolu do zastosowania w leczeniu i zapobieganiu przemijającym atakom niedokrwiennym neuronów
US20230020342A1 (en) * 2019-06-12 2023-01-19 Ioi Oleo Gmbh Method for producing polyol-based esters, in particular polyglycerol esters, from hydroxy carboxylic acids
JP7546828B2 (ja) * 2019-06-12 2024-09-09 ケトリピックス セラポーティクス ゲーエムベーハー ケトカルボン酸のポリオールベースのエステルの製造方法
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
EP4146337B1 (de) * 2020-07-13 2024-04-17 KetoLipix Therapeutics GmbH Verfahren zur herstellung von polyglycerinestern von mit oxobutanol veresterten polycarbonsäuren
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
EP4366720A4 (en) * 2021-07-09 2025-05-07 Georgia State University Research Foundation, Inc. The use of beta-hydroxybutyrates for the treatment or prevention of aneurysms and dissections
MX2024005533A (es) 2021-11-12 2024-07-29 Arxada Ag Compuestos derivados de polioles.
US20250002446A1 (en) 2021-11-26 2025-01-02 Arxada Ag Acetoacetate Based Ketals
US12023382B2 (en) 2022-01-18 2024-07-02 Today Inc. Molecules, formulations, and methods for nutritional support of athletes, patients, and others
WO2023139357A1 (en) * 2022-01-18 2023-07-27 Today Inc. Molecules, nutritional formulations, and methods of providing nutritional support
US20230277484A1 (en) * 2022-03-04 2023-09-07 Guardian Biosciences, LLC Compositions and methods to promote brain health
WO2024083889A1 (en) 2022-10-18 2024-04-25 Arxada Ag Polyol-derived compounds
WO2025074001A2 (en) 2023-10-05 2025-04-10 Arxada Ag Enzymatic reduction of acetoacetate
WO2025196156A1 (en) 2024-03-20 2025-09-25 Arxada Ag Continuous hydrogenation process of acetoacetate esters
WO2025224319A1 (en) 2024-04-25 2025-10-30 Arxada Ag Reduction of acetoacetate esters in the presence of amines

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4598203B2 (ja) * 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド 脳機能改善剤
US6323237B1 (en) 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
CA2283642C (en) * 1997-03-17 2012-05-15 Btg International Limited Therapeutic compositions
US8124589B2 (en) 2000-05-01 2012-02-28 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
GB0420856D0 (en) * 2004-09-20 2004-10-20 Ketocytonyx Inc Cns modulators
WO2006128006A1 (en) 2005-05-26 2006-11-30 The Regents Of The University Of Colorado Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
US7807718B2 (en) 2006-06-30 2010-10-05 Sami A. Hashim Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
BRPI0811052A2 (pt) 2007-04-12 2015-01-27 Univ Minnesota Composições de proteção de isquemia/reperfusão e métodos de uso.
JP2009173766A (ja) 2008-01-24 2009-08-06 Ono Kogei Kk 炭素繊維含有コーティング組成物およびその調製方法
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
WO2010084356A1 (en) 2009-01-24 2010-07-29 Phytopharm Plc Treatment of neurotrophic factor mediated disorders
GB201002983D0 (en) * 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
CA2873057C (en) 2011-05-09 2020-02-25 University Of South Florida The use of ketone esters for prevention of cns oxygen toxicity
US20140072654A1 (en) 2011-12-23 2014-03-13 Savind, Inc. Cancer with metabolic therapy and hyperbaric oxygen
FR2997302B1 (fr) 2012-10-29 2015-02-06 Assist Publ Hopitaux De Paris Prevention et traitement des deficits en pyruvate deshydrogenase
EP2914251B1 (en) 2012-11-05 2019-08-21 The United States of America, as represented by The Secretary, Department of Health and Human Services Ketone bodies to protect tissues from damage by ionizing radiation
WO2014085652A1 (en) 2012-11-28 2014-06-05 University Of South Florida Targeting cancer with metabolic therapy and hyperbaric oxygen
KR102499654B1 (ko) 2013-03-19 2023-02-13 유니버시티 오브 사우스 플로리다 상승되고 지속되는 케톤증을 생성하기 위한 조성물 및 방법
WO2015034812A2 (en) * 2013-09-04 2015-03-12 Beth Israel Deaconess Medical Center A new ketogenic diet and its use in treating the critically ill
WO2015156865A1 (en) 2014-01-13 2015-10-15 University Of South Florida Methods of sustaining dietary ketosis and its effects on lipid profile
US20160078782A1 (en) 2014-09-17 2016-03-17 The Trustees Of Boston College Glucose Ketone Index for MetabolicTherapy
US9364456B1 (en) 2015-06-30 2016-06-14 University Of South Florida Ketone esters for treatment of angelman syndrome
US20180200220A1 (en) 2015-07-10 2018-07-19 Cognate Nutritionals, Inc. Prophylaxis and mitigation of migraine headaches using ketogenic medium chain triglycerides, ketone esters, and other ketogenic sources
US10292952B2 (en) 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
WO2017165445A1 (en) 2016-03-21 2017-09-28 Csilla Ari D'agostino Administration of exogenous ketone to lower blood glucose
US10376482B2 (en) 2016-04-03 2019-08-13 Franco Cavaleri Butyrate and beta-hydroxybutyrate compositions
CA3021784A1 (en) 2016-04-19 2017-10-26 Keto Patent Group, Inc. Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
WO2018009208A1 (en) 2016-07-08 2018-01-11 Cognate Nutritionals, Inc. Nutritional mitiggation of the cns effects of traumatic brain injury
US10588877B2 (en) 2016-07-21 2020-03-17 Savind, Inc. Compositions comprising β-hydroxybutyric acid and salt, and methods of using the same
US20180057846A1 (en) 2016-08-30 2018-03-01 KetoneAid Inc. Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy
US20180055797A1 (en) 2016-08-31 2018-03-01 KetoneAid Inc. Non-racemic ketone salts for rapid-onset nutritional ketosis and metabolic therapy
CN109890381A (zh) 2016-09-12 2019-06-14 南佛罗里达大学 酮改善神经再生

Also Published As

Publication number Publication date
EP3568129A4 (en) 2020-12-09
US9925164B1 (en) 2018-03-27
IL267934B2 (en) 2024-09-01
BR112019014128A2 (pt) 2020-06-16
JP2020504134A (ja) 2020-02-06
CN110114067A (zh) 2019-08-09
WO2018132189A1 (en) 2018-07-19
CA3046355A1 (en) 2018-07-19
US20180193300A1 (en) 2018-07-12
US20200297686A1 (en) 2020-09-24
IL267934B1 (en) 2024-05-01
MX2019008269A (es) 2019-09-13
MY207193A (en) 2025-02-05
CA3046355C (en) 2023-08-01
IL267934A (en) 2019-09-26
EP3568129A1 (en) 2019-11-20
JP7278593B2 (ja) 2023-05-22
KR20190104546A (ko) 2019-09-10
US10736867B2 (en) 2020-08-11
KR102443942B1 (ko) 2022-09-15
US11638702B2 (en) 2023-05-02

Similar Documents

Publication Publication Date Title
MX391851B (es) Gliceril 3-hidroxibutiratos para las lesiones cerebrales traumaticas
MX392869B (es) Kit para el tratamiento o alivio de dolor en el sitio de incision despues de un procedimiento quirurgico
WO2015021434A3 (en) Methods and apparatuses for skin treatment using non-thermal tissue ablation
EA201490746A2 (ru) Применение прогестерона при профилактике и после острого периода для улучшения исходов, связанных с сотрясением мозга
MY194341A (en) Method of treating a brain tumor
GB2604876B (en) Skin treatment device
PH12017500392A1 (en) Medical treatments based on anamorelin
SG11202007082PA (en) Composition used for therapeutic treatment of skin disease
PL4452256T3 (pl) Metody leczenia guzów mózgu i nerwiaków niedojrzałych
ZA202002075B (en) Compounds, compositions and methods for treatment of eye disorders and skin diseases
IL271632A (en) Implant for injured nerve tissue prosthetics, method of surgical treatment for injured nerve tissue and use of porous polytetrafluorethylene
IL304628A (en) Treatment of skin disorders
ZA202002910B (en) Treatment of skin disorders
SMT202500404T1 (it) Trattamento combinato di compromissione del cervello
CA207484S (en) Skin treatment device
CA207483S (en) Skin treatment device
GB202001353D0 (en) Treatment of skin conditions
EP3585434A4 (en) METHOD OF PHOTOCHEMICAL TREATMENT FOR WOUND HEALING
MX2015009483A (es) Pinzas para reparacion percutanea de tendon de aquiles por minima invasion.
CA207482S (en) Skin treatment device
GB202116774D0 (en) Treatment of pain
EP3010532A4 (en) Materials for positive cathepsin b modulation and methods of use for treating mild cognitive impairment (mci), early dementia, a-synucleinopathy, traumatic brain injury, cardiomyopathy, eye disease and skin damage
GB202114129D0 (en) Treatment of traumatic brain injury
GB202100566D0 (en) Treatment of brain damage
GB202107701D0 (en) Treatment of traumatic brain injury